Verrica Pharmaceuticals (VRCA) Competitors $0.64 -0.01 (-0.79%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. VYGR, YMAB, IVA, CRDF, PRME, INMB, TLSA, MOLN, ELDN, and CTMXShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), Inventiva (IVA), Cardiff Oncology (CRDF), Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Voyager Therapeutics Y-mAbs Therapeutics Inventiva Cardiff Oncology Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals CytomX Therapeutics Verrica Pharmaceuticals (NASDAQ:VRCA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Do analysts recommend VRCA or VYGR? Verrica Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 1,153.92%. Voyager Therapeutics has a consensus target price of $13.39, suggesting a potential upside of 299.11%. Given Verrica Pharmaceuticals' higher probable upside, equities analysts clearly believe Verrica Pharmaceuticals is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to VRCA or VYGR? In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 8 articles in the media. Voyager Therapeutics' average media sentiment score of 0.67 beat Verrica Pharmaceuticals' score of 0.44 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, VRCA or VYGR? Voyager Therapeutics has higher revenue and earnings than Verrica Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M7.80-$67M-$1.20-0.53Voyager Therapeutics$66.96M2.77$132.33M-$1.46-2.30 Which has more volatility and risk, VRCA or VYGR? Verrica Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Is VRCA or VYGR more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Verrica Pharmaceuticals' net margin of -625.06%. Voyager Therapeutics' return on equity of 8.33% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Verrica Pharmaceuticals-625.06% -591.84% -141.63% Voyager Therapeutics 15.80%8.33%6.15% Do insiders and institutionals hold more shares of VRCA or VYGR? 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer VRCA or VYGR? Voyager Therapeutics received 234 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 67.97% of users gave Voyager Therapeutics an outperform vote while only 63.02% of users gave Verrica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVerrica PharmaceuticalsOutperform Votes16763.02% Underperform Votes9836.98% Voyager TherapeuticsOutperform Votes40167.97% Underperform Votes18932.03% SummaryVoyager Therapeutics beats Verrica Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.38M$6.54B$5.42B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.359.1426.7820.05Price / Sales7.80255.59395.49116.44Price / CashN/A65.8538.2534.62Price / Book1.366.546.874.61Net Income-$67M$143.51M$3.22B$248.19M7 Day Performance19.19%5.60%5.69%2.56%1 Month Performance37.09%10.06%12.66%16.18%1 Year Performance-92.73%-0.86%18.01%8.16% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.2859 of 5 stars$0.64-0.8%$8.00+1,153.9%-92.6%$59.38M$7.57M-0.3540Analyst RevisionVYGRVoyager Therapeutics4.6952 of 5 stars$3.35+5.7%$13.97+316.9%-59.8%$185.30M$80.00M4.72100Gap UpYMABY-mAbs Therapeutics3.5045 of 5 stars$4.07+4.6%$17.40+327.5%-64.2%$184.28M$87.69M-7.54150Analyst ForecastAnalyst RevisionIVAInventiva1.5076 of 5 stars$3.51-3.0%$10.40+196.3%-17.1%$184.19M$9.20M0.00100Gap DownCRDFCardiff Oncology1.5792 of 5 stars$2.75+3.4%$12.00+336.4%-13.3%$182.95M$683,000.00-2.9320Gap UpPRMEPrime Medicine3.7678 of 5 stars$1.34+3.1%$13.14+880.8%-84.4%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastINMBINmune Bio1.9905 of 5 stars$7.64+9.6%$22.80+198.4%-31.6%$175.60M$14,000.00-3.5010Gap UpTLSATiziana Life Sciences1.0659 of 5 stars$1.50-4.5%N/A+94.8%$175.27MN/A0.008Gap UpMOLNMolecular Partners1.9779 of 5 stars$4.28+4.4%$12.00+180.4%+5.6%$172.81M$4.97M-1.99180News CoveragePositive NewsEarnings ReportAnalyst RevisionELDNEledon Pharmaceuticals2.1861 of 5 stars$2.87-0.7%$12.50+335.5%-1.9%$171.86MN/A-1.4310News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpCTMXCytomX Therapeutics4.2913 of 5 stars$2.13+129.4%$3.75+76.1%+7.3%$171.72M$138.10M12.53170Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies VYGR Alternatives YMAB Alternatives IVA Alternatives CRDF Alternatives PRME Alternatives INMB Alternatives TLSA Alternatives MOLN Alternatives ELDN Alternatives CTMX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
